MHRA – Page 189 – Pharma.Tips

Pet Failure after excipient change: packaging integrity and stability justification

Investigating Pet Failure Following an Excipient Change in Pharmaceutical Manufacturing Pharmaceutical manufacturers often face challenges when introducing new excipients in formulation processes, particularly with sensitive dosage forms such as rectal…

Microbial Limits Failure in suppository manufacturing: GMP investigation and batch disposition

Understanding the Investigation Process for Microbial Limits Failure in Suppository Manufacturing Microbial limits failure during the manufacturing of suppositories can lead to significant regulatory scrutiny and potential product recalls. Such…

Particulate Matter Oos after packaging change: packaging integrity and CCIT justification

Investigation into OOS for Particulate Matter Post Packaging Change In the pharmaceutical manufacturing landscape, ensuring the integrity of products is critical, especially for sensitive dosage forms such as ophthalmics. A…

Microbial Limits Failure in vaginal gel production: process controls for moulding, filling, and storage

Assessing Microbial Limits Failure during Vaginal Gel Production: Effective Process Controls In pharmaceutical manufacturing, ensuring product quality and compliance with microbial limits is paramount. A deviation related to microbial limits…

Cleaning Validation Failure during inspection readiness: CAPA with effectiveness checks for auditors

Addressing Cleaning Validation Failures to Ensure Inspection Readiness Cleaning validation failures during inspection readiness present significant challenges for pharmaceutical manufacturers, especially in dosage forms like rectal and vaginal products. Such…

Osmolality Oos during method transfer: how to avoid repeat 483 observations

Managing Osmolality OOS During Method Transfer to Prevent Regulatory Action Osmolality Out of Specification (OOS) results during method transfers present a significant challenge to pharmaceutical manufacturers, particularly in the development…

Ph Drift during inspection readiness: GMP investigation and batch disposition

GMP Investigations into pH Drift During Inspection Readiness and Batch Disposition In the dynamic environment of pharmaceutical manufacturing, particularly in the production of rectal and vaginal dosage forms, maintaining critical…

Cleaning Validation Failure in suppository manufacturing: manufacturing vs lab root cause decision tree

Root Cause Investigation of Cleaning Validation Failures in Suppository Manufacturing In the pharmaceutical industry, ensuring compliance with cleaning validation protocols is critical, particularly in the production of suppositories. Despite the…

Pet Failure in suppository manufacturing: manufacturing vs lab root cause decision tree

Understanding Pet Failures in Suppository Manufacturing: A Decision Tree for Root Cause Investigation The manufacturing of suppositories, characterized by its unique formulation and delivery mechanisms, presents particular challenges that manufacturing…

Tag: MHRA